Hormonal
Essential fatty acids (EFAs) and their long-chain metabolites (EPA, DHA, GLA, DGLA, AA) function as endogenous inhibitors of HMG-CoA reductase and ACE, providing cardioprotective, anti-hypertensive, and anti-atherosclerotic benefits comparable to a pharmaceutical 'polypill'.
To support heart health and blood pressure naturally, ensure your diet includes adequate sources of essential fatty acids. This means balancing omega-3s (from fish, flax, walnuts) and omega-6s (from plant oils like sunflower or safflower, and some animal sources). The paper suggests that maintaining adequate levels of these fats, rather than relying solely on synthetic drugs, may help regulate cholesterol and blood pressure through your body's own enzymatic processes. Focus on whole food sources and consider the ratio of omega-3 to omega-6, aiming for a balance closer to 1:1 or 2:3 rather than the modern industrial ratio of 10:1 or higher.
Essential fatty acids (EFAs) and their long-chain metabolites: γ-linolenic acid (GLA), dihomog-GLA (DGLA), arachidonic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)... prevent platelet aggregation, lower blood pressure, have anti-arrhythmic action, reduce LDL-C... Thus, EFAs and their metabolites show all the classic actions expected of the 'polypill'.
Why this rating
The paper is a hypothesis/review article citing observational and animal studies, lacking large-scale randomized controlled trials for the specific 'EFA polypill' equivalence.
Source
Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules
Undurti N. Das · Lipids in Health and Disease · 2008
DOI 10.1186/1476-511x-7-37
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →